Key Takeaways Alnylam Pharmaceuticals announced a Phase-3 study of its treatment for a rare heart condition showed a significant reduction in deaths and recurrent cardiovascular events. The biopharmaceutical company said it would be seeking regulatory approval later this year, including asking the Food and Drug Administration for a priority review. The news sent shares of Alnylam soaring over 31% in early trading Monday. Shares of Alnylam Pharmaceuticals (ALNY) skyrocketed over 31% in early trading Monday a ...